Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer

Molecular targeted therapies are the standard of care for front‐line treatment of metastatic non‐small‐cell lung cancers (NSCLCs) harboring driver gene mutations. However, despite the initial dramatic responses, the emergence of acquired resistance is inevitable. Acquisition of secondary mutations i...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Takamasa, Suda, Kenichi, Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898722/
https://www.ncbi.nlm.nih.gov/pubmed/34997674
http://dx.doi.org/10.1111/cas.15263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898722/
https://www.ncbi.nlm.nih.gov/pubmed/34997674
http://dx.doi.org/10.1111/cas.15263

Ejemplares similares